RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma
Interventions: DRUG: Gamma-Secretase Inhibitor RO4929097|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacogenomic Study|OTHER: Pharmacological Study|DRUG: Vismodegib
Sponsor: National Cancer Institute (NCI)